| Filed | Form | Description | |
|---|---|---|---|
| 11/28/25 | DEF 14A | DEF 14A | → |
| 11/19/25 | PRE 14A | FORM PRE 14A | → |
| 6/25/24 | DEFA14A | DEFA14A | → |
| 6/3/24 | DEF 14A | DEF 14A | → |
| 5/22/24 | PRE 14A | PRE 14A | → |
| 12/23/22 | DEFA14A | DEFA14A | → |
| ↓ | |||
| Filed | Form | Description | |
|---|---|---|---|
| 9/3/24 | 4 | OWNERSHIP DOCUMENT | → |
| 8/13/24 | 4 | OWNERSHIP DOCUMENT | → |
| 8/8/24 | 4 | OWNERSHIP DOCUMENT | → |
| 7/30/24 | 4 | OWNERSHIP DOCUMENT | → |
| 12/1/23 | 4 | OWNERSHIP DOCUMENT | → |
| 4/5/23 | 4 | OWNERSHIP DOCUMENT | → |
| ↓ | |||
Northwest Biotherapeutics, Inc. is a development-stage American pharmaceutical company headquartered in Maryland that focuses on developing immunotherapies against different types of cancer.